Sayaka Nagata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sayaka Nagata has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Kazuo Kitamura
Department of Project Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan
9 shared publications - Johji Kato
Frontier Science Research Center, University of Miyazaki Faculty of Medicine, Miyazaki 889-1692, Japan
5 shared publications Kazuo Kitamura
Circulatory and Body Fluid Regulation, University of Miyazaki , 5200 Kihara, Kiyotake, Miyazaki 889-1692
5 shared publicationsMotoo Yamasaki
Circulatory and Body Fluid Regulation, University of Miyazaki , 5200 Kihara, Kiyotake, Miyazaki 889-1692
4 shared publications- Motoo Yamasaki
Department of Project Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan
4 shared publications Emiko Akashi
Circulatory and Body Fluid Regulation, University of Miyazaki , 5200 Kihara, Kiyotake, Miyazaki 889-1692
2 shared publications
Latest Publications
- Open Access
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9373
In Vitro and In Vivo Characterization of 40 kDa PEGylated Adrenomedullin in a DSS-Induced Colitis Model
Adrenomedullin (AM), a biologically active peptide, induces complete remission with mucosal healing in patients with refractory ulcerative colitis. We have developed 40 kDa PEGylated AM (PEG-AM), a long-acting AM derivative, as a potential therapeutic agent for inflammatory bowel disease (IBD). Both PEG-AM and native AM stimulated cyclic adenosine monophosphate (cAMP) production in HEK-293 cells stably expressing the AM1 receptor (CLR/RAMP2 complex), in a dose-dependent manner. The pEC50 values for PEG-AM and AM were 7.23 ± 0.05 and 8.42 ± 0.10, respectively. PEG-AM exhibited significantly greater stability in plasma and serum than native AM. We evaluated the in vivo anti-colitis effects of intravenously administered PEG-AM in a dextran sodium sulfate (DSS)-induced murine colitis model. A single intravenous dose of PEG-AM, as low as 25 nmol/kg, demonstrated therapeutic efficacy. Notably, AM receptor expression was not downregulated, despite sustained high plasma concentrations of PEG-AM. Additionally, PEG-AM exerted both therapeutic and preventive effects in a DSS colitis model. These findings suggest that PEG-AM is a promising therapeutic candidate for the treatment of patients with IBD.
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9373
Open AccessIn Vitro and In Vivo Characterization of 40 kDa PEGylated Adrenomedullin in a DSS-Induced Colitis Model
Adrenomedullin (AM), a biologically active peptide, induces complete remission with mucosal healing in patients with refractory ulcerative colitis. We have developed 40 kDa PEGylated AM (PEG-AM), a long-acting AM derivative, as a potential therapeutic agent for inflammatory bowel disease (IBD). Both PEG-AM and native AM stimulated cyclic adenosine monophosphate (cAMP) production in HEK-293 cells stably expressing the AM1 receptor (CLR/RAMP2 complex), in a dose-dependent manner. The pEC50 values for PEG-AM and AM were 7.23 ± 0.05 and 8.42 ± 0.10, respectively. PEG-AM exhibited significantly greater stability in plasma and serum than native AM. We evaluated the in vivo anti-colitis effects of intravenously administered PEG-AM in a dextran sodium sulfate (DSS)-induced murine colitis model. A single intravenous dose of PEG-AM, as low as 25 nmol/kg, demonstrated therapeutic efficacy. Notably, AM receptor expression was not downregulated, despite sustained high plasma concentrations of PEG-AM. Additionally, PEG-AM exerted both therapeutic and preventive effects in a DSS colitis model. These findings suggest that PEG-AM is a promising therapeutic candidate for the treatment of patients with IBD.
- Open Access
Development of Long-Acting Human Adrenomedullin Fc-Fusion Proteins
(1) Background: Human adrenomedullin (hAM) is a hypotensive peptide hormone that exerts powerful anti-inflammatory effects. AM also had therapeutic effects in various animal experimental models of disease. However, treatment required continuous administration as the half-life of native AM is short in blood. To resolve this, we developed four human IgG1 and IgG4 Fc-fusion proteins containing full-length hAM or hAM residues 6-52. (2) Methods: We used mammalian cells to produce recombinant Fc-AM derivatives and tested the pharmacokinetics and biological activity of Fc-AM. (3) Results: We developed four Fc-fusion AMs (Fc-AM), which are long-acting AM derivatives in mammalian cells. Fc-AM had a prolonged half-life in blood and retained its ability to bind to the AM1 receptor. Fc-AM (6-52) induced higher cAMP levels for the receptor than Fc-AM. After the administration of IgG1-AM (6-52) or IgG4-AM (6-52) to rats, tissue transfer to the kidney and small intestine was observed. In addition, treatment with IgG4-AM (6-52) inhibited blood pressure increase in spontaneously hypertensive rats. (4) Conclusions: Fc-AM produced from mammalian cells can be easily prepared and might be an effective novel therapeutic agent.
Open AccessDevelopment of Long-Acting Human Adrenomedullin Fc-Fusion Proteins
(1) Background: Human adrenomedullin (hAM) is a hypotensive peptide hormone that exerts powerful anti-inflammatory effects. AM also had therapeutic effects in various animal experimental models of disease. However, treatment required continuous administration as the half-life of native AM is short in blood. To resolve this, we developed four human IgG1 and IgG4 Fc-fusion proteins containing full-length hAM or hAM residues 6-52. (2) Methods: We used mammalian cells to produce recombinant Fc-AM derivatives and tested the pharmacokinetics and biological activity of Fc-AM. (3) Results: We developed four Fc-fusion AMs (Fc-AM), which are long-acting AM derivatives in mammalian cells. Fc-AM had a prolonged half-life in blood and retained its ability to bind to the AM1 receptor. Fc-AM (6-52) induced higher cAMP levels for the receptor than Fc-AM. After the administration of IgG1-AM (6-52) or IgG4-AM (6-52) to rats, tissue transfer to the kidney and small intestine was observed. In addition, treatment with IgG4-AM (6-52) inhibited blood pressure increase in spontaneously hypertensive rats. (4) Conclusions: Fc-AM produced from mammalian cells can be easily prepared and might be an effective novel therapeutic agent.
- 8 May 2021
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 170 (4) , 445-451
Development of a novel human adrenomedullin derivative: human serum albumin-conjugated adrenomedullin
Adrenomedullin is a biologically active peptide with multiple functions. Here, we have developed a novel human serum albumin-adrenomedullin (HSA-AM) conjugate, which was synthesized by the covalent attachment of a maleimide derivative of adrenomedullin to the 34th cysteine residue of HSA via a linker. Denaturing gel electrophoresis and western blotting for HSA-AM yielded a single band with adrenomedullin immunoreactivity at the position corresponding to a molecular weight (MW) of 73 kDa. Following gel-filtration chromatography, the purified HSA-AM showed a single main peak corresponding with an MW of 73 kDa, indicating that HSA-AM is a monomer. Both adrenomedullin and HSA-AM stimulated the intracellular accumulation of cyclic AMP (cAMP) in HEK-293 cells stably expressing the adrenomedullin 1 receptor. The pEC50 values for adrenomedullin and HSA-AM were 8.660 and 7.208 (equivalent to 2.19 and 61.9 nM as EC50), respectively. The bioavailability of HSA-AM compared with that of adrenomedullin was much improved after subcutaneous administration in the rat, which was probably due to the superior resistance of HSA-AM towards endogenous proteases and its reduced clearance from the blood. HSA-AM may be a promising drug candidate for clinical application.
- 8 May 2021
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 170 (4) , 445-451
Development of a novel human adrenomedullin derivative: human serum albumin-conjugated adrenomedullin
Adrenomedullin is a biologically active peptide with multiple functions. Here, we have developed a novel human serum albumin-adrenomedullin (HSA-AM) conjugate, which was synthesized by the covalent attachment of a maleimide derivative of adrenomedullin to the 34th cysteine residue of HSA via a linker. Denaturing gel electrophoresis and western blotting for HSA-AM yielded a single band with adrenomedullin immunoreactivity at the position corresponding to a molecular weight (MW) of 73 kDa. Following gel-filtration chromatography, the purified HSA-AM showed a single main peak corresponding with an MW of 73 kDa, indicating that HSA-AM is a monomer. Both adrenomedullin and HSA-AM stimulated the intracellular accumulation of cyclic AMP (cAMP) in HEK-293 cells stably expressing the adrenomedullin 1 receptor. The pEC50 values for adrenomedullin and HSA-AM were 8.660 and 7.208 (equivalent to 2.19 and 61.9 nM as EC50), respectively. The bioavailability of HSA-AM compared with that of adrenomedullin was much improved after subcutaneous administration in the rat, which was probably due to the superior resistance of HSA-AM towards endogenous proteases and its reduced clearance from the blood. HSA-AM may be a promising drug candidate for clinical application.
- 30 December 2020
- Published by Wiley in Nephrology
- Vol. 26 (5) , 479-484
Development of a novel AlphaLISA ImmunoAssay for Big angiotensin‐25
We previously described the discovery of Big angiotensin‐25 (Bang‐25), an angiotensin‐related peptide isolated from human urine. Bang‐25 consists of the first 25 amino acids of the N‐terminus of angiotensinogen (Aogen), with N‐linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid. Bang‐25 is rapidly converted into angiotensin II (Ang II) by chymase. Because Bang‐25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues. To test this hypothesis, we developed a specific assay for Bang‐25 and used it to examine the urinary concentrations of Bang‐25 in patients with diabetes mellitus (DM). The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)‐based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N‐terminus of Ang II and the C‐terminus of Bang‐25. The AlphaLISA ImmunoAssay specifically recognized Bang‐25 and had no cross‐reactivity with Aogen or Ang I. Bang‐25 was detected in healthy volunteers' urine samples but not in their plasma samples. In patients with DM, the urinary Bang‐25 concentration was significantly higher than in healthy volunteers. Moreover, the results indicated that the Bang‐25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin. This assay could provide a useful tool for determining urinary Bang‐25, which may prove an important biomarker for diabetic kidney disease.
- 30 December 2020
- Published by Wiley in Nephrology
- Vol. 26 (5) , 479-484
Development of a novel AlphaLISA ImmunoAssay for Big angiotensin‐25
We previously described the discovery of Big angiotensin‐25 (Bang‐25), an angiotensin‐related peptide isolated from human urine. Bang‐25 consists of the first 25 amino acids of the N‐terminus of angiotensinogen (Aogen), with N‐linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid. Bang‐25 is rapidly converted into angiotensin II (Ang II) by chymase. Because Bang‐25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues. To test this hypothesis, we developed a specific assay for Bang‐25 and used it to examine the urinary concentrations of Bang‐25 in patients with diabetes mellitus (DM). The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)‐based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N‐terminus of Ang II and the C‐terminus of Bang‐25. The AlphaLISA ImmunoAssay specifically recognized Bang‐25 and had no cross‐reactivity with Aogen or Ang I. Bang‐25 was detected in healthy volunteers' urine samples but not in their plasma samples. In patients with DM, the urinary Bang‐25 concentration was significantly higher than in healthy volunteers. Moreover, the results indicated that the Bang‐25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin. This assay could provide a useful tool for determining urinary Bang‐25, which may prove an important biomarker for diabetic kidney disease.
- Open Access
- 1 November 2020
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 43 (11) , 1799-1803
Activation of Calcitonin Gene-Related Peptide and Adrenomedullin Receptors by PEGylated Adrenomedullin
Adrenomedullin (AM) improves colitis in animal models and patients with inflammatory bowel disease. We have developed a PEGylated AM derivative (PEG-AM) for clinical application because AM has a short half-life in the blood. However, modification by addition of polyethylene glycol (PEG) may compromise the function of the original peptide. In this paper, we examined the time course of cAMP accumulation induced by 5 and 60 kDa PEG-AM and compared the activation of calcitonin gene-related peptide (CGRP), AM1 and AM2 receptors by AM, 5 and 60 kDa PEG-AM. We also evaluated the effects of antagonists on the action of 5 and 60 kDa PEG-AM. PEG-AM stimulated cAMP production induced by these receptors; the increase in cAMP levels resulting from application of PEG-AM peaked at 15 min. Moreover, PEG-AM activity was antagonized by CGRP (8–37) or AM (22–52) (antagonists of CGRP and AM receptors, respectively) and the maximal response was not suppressed. These findings indicate that the effects of PEG-AM are similar to those of native AM.
- 1 November 2020
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 43 (11) , 1799-1803
Open AccessActivation of Calcitonin Gene-Related Peptide and Adrenomedullin Receptors by PEGylated Adrenomedullin
Adrenomedullin (AM) improves colitis in animal models and patients with inflammatory bowel disease. We have developed a PEGylated AM derivative (PEG-AM) for clinical application because AM has a short half-life in the blood. However, modification by addition of polyethylene glycol (PEG) may compromise the function of the original peptide. In this paper, we examined the time course of cAMP accumulation induced by 5 and 60 kDa PEG-AM and compared the activation of calcitonin gene-related peptide (CGRP), AM1 and AM2 receptors by AM, 5 and 60 kDa PEG-AM. We also evaluated the effects of antagonists on the action of 5 and 60 kDa PEG-AM. PEG-AM stimulated cAMP production induced by these receptors; the increase in cAMP levels resulting from application of PEG-AM peaked at 15 min. Moreover, PEG-AM activity was antagonized by CGRP (8–37) or AM (22–52) (antagonists of CGRP and AM receptors, respectively) and the maximal response was not suppressed. These findings indicate that the effects of PEG-AM are similar to those of native AM.
- Open Access
- 7 October 2020
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 2 (4) , 366-377
20 kDa PEGylated Adrenomedullin as a New Therapeutic Candidate for Inflammatory Bowel Disease
Human adrenomedullin (AM), a hypotensive peptide, also has anti-colitis activity. We prepared a polyethylene glycol (PEG) ylated form of AM through the conjugation of PEG-AM (1–15) and AM (15–52). Highly pure monomeric 20 kDa PEG-AM (20kPEG-AM) stimulated cyclic adenosine monophosphate production in HEK-293 cells stably expressing the type 1 AM receptor in a dose-dependent manner. The half-life of 20kPEG-AM was 7.4 h following subcutaneous administration in mice. We assessed the anti-colitis effect of subcutaneous 20kPEG-AM administration in the dextran sodium sulfate murine colitis model. Single and double subcutaneous injection of 20kPEG-AM significantly reduced total inflammation scores. These results suggest that 20kPEG-AM is a promising therapeutic candidate for the treatment of human inflammatory bowel diseases.
- 7 October 2020
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 2 (4) , 366-377
Open Access20 kDa PEGylated Adrenomedullin as a New Therapeutic Candidate for Inflammatory Bowel Disease
Human adrenomedullin (AM), a hypotensive peptide, also has anti-colitis activity. We prepared a polyethylene glycol (PEG) ylated form of AM through the conjugation of PEG-AM (1–15) and AM (15–52). Highly pure monomeric 20 kDa PEG-AM (20kPEG-AM) stimulated cyclic adenosine monophosphate production in HEK-293 cells stably expressing the type 1 AM receptor in a dose-dependent manner. The half-life of 20kPEG-AM was 7.4 h following subcutaneous administration in mice. We assessed the anti-colitis effect of subcutaneous 20kPEG-AM administration in the dextran sodium sulfate murine colitis model. Single and double subcutaneous injection of 20kPEG-AM significantly reduced total inflammation scores. These results suggest that 20kPEG-AM is a promising therapeutic candidate for the treatment of human inflammatory bowel diseases.
- 1 August 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 529 (3) , 778-783
Thrombin rapidly digests adrenomedullin: Synthesis of adrenomedullin analogs resistant to thrombin
- 1 August 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 529 (3) , 778-783
Thrombin rapidly digests adrenomedullin: Synthesis of adrenomedullin analogs resistant to thrombin
- 27 April 2017
- Published by Wiley in Drug Development Research
- Vol. 78 (3-4) , 129-134
Anti‐Inflammatory Effects of PEGylated Human Adrenomedullin in a Mouse DSS‐Induced Colitis Model
Preclinical Research Human adrenomedullin (hAM), a hypotensive peptide, also has anti‐inflammatory effects. hAM can reduce the severity of the dextran sulphate sodium (DSS)‐ and 2,4,6‐trinitrobenzene sulfonic acid (TNBS)‐induced colitis in animal models. Furthermore, in a clinical study, hAM treatment reduced the Disease Activity Index in ulcerative colitis. However, these therapeutic effects required continuous administration of hAM as the half‐life of native hAM is quite short in blood. To resolve this problem, hAM N‐terminal was conjugated with two kinds of polyethylene glycol (PEG); 5 kDa PEG or 60 kDa PEG (5 kDa PEG‐hAM and 60 kDa PEG‐hAM respectively). In a previous study, 5 kDa PEG‐hAM stimulated cAMP production and prolonged the plasma half‐life compared with native hAM. Herein we examine the effect of PEG‐hAM in the DSS colitis model. Treatment with both PEG‐hAM preparations reduced the total inflammation score. In addition, the plasma half‐life of 60 kDa PEG‐hAM was much longer than 5 kDa PEG‐hAM. In summary, a single subcutaneous administration of 60 kDa PEG‐hAM reduced the total inflammation score in mice with DSS‐induced colitis. Therefore, these results suggest that 60 kDa PEG‐hAM is a possible therapeutic agent for the treatment of inflammatory bowel disease. Drug Dev Res 78 : 129‐134, 2017.
- 27 April 2017
- Published by Wiley in Drug Development Research
- Vol. 78 (3-4) , 129-134
Anti‐Inflammatory Effects of PEGylated Human Adrenomedullin in a Mouse DSS‐Induced Colitis Model
Preclinical Research Human adrenomedullin (hAM), a hypotensive peptide, also has anti‐inflammatory effects. hAM can reduce the severity of the dextran sulphate sodium (DSS)‐ and 2,4,6‐trinitrobenzene sulfonic acid (TNBS)‐induced colitis in animal models. Furthermore, in a clinical study, hAM treatment reduced the Disease Activity Index in ulcerative colitis. However, these therapeutic effects required continuous administration of hAM as the half‐life of native hAM is quite short in blood. To resolve this problem, hAM N‐terminal was conjugated with two kinds of polyethylene glycol (PEG); 5 kDa PEG or 60 kDa PEG (5 kDa PEG‐hAM and 60 kDa PEG‐hAM respectively). In a previous study, 5 kDa PEG‐hAM stimulated cAMP production and prolonged the plasma half‐life compared with native hAM. Herein we examine the effect of PEG‐hAM in the DSS colitis model. Treatment with both PEG‐hAM preparations reduced the total inflammation score. In addition, the plasma half‐life of 60 kDa PEG‐hAM was much longer than 5 kDa PEG‐hAM. In summary, a single subcutaneous administration of 60 kDa PEG‐hAM reduced the total inflammation score in mice with DSS‐induced colitis. Therefore, these results suggest that 60 kDa PEG‐hAM is a possible therapeutic agent for the treatment of inflammatory bowel disease. Drug Dev Res 78 : 129‐134, 2017.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e99
[PS 01-11] BIOCHEMICAL PROPERTIES OF THE N-TERMINALLY PALMITOYLATED ADRENOMEDULLIN
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e99
[PS 01-11] BIOCHEMICAL PROPERTIES OF THE N-TERMINALLY PALMITOYLATED ADRENOMEDULLIN